---
layout: post
title: "Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment; Guidance for Industry; Availability"
date: 2026-02-05 18:59:38 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-13752
original_published: 2022-06-28 00:00:00 +0000
significance: 8.00
---

# Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** June 28, 2022 00:00 UTC
**Document Number:** 2022-13752

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment." This guidance is intended to facilitate the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma and provides recommendations for the sponsor on this topic. The guidance includes recommendations regarding eligibility criteria, choice of comparator, followup imaging assessments, determination of disease recurrence, analyses of disease-free survival, and interpretation of trial results. This guidance finalizes the draft guidance of the same title issued on October 2, 2020.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/06/28/2022-13752/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-13752

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
